Log In
Print this Print this

Norovirus VLP intramuscular vaccine (TAK-214)

  Manage Alerts
Collapse Summary General Information
Company Takeda Pharmaceutical Co. Ltd.
DescriptionBivalent virus-like particle (VLP) vaccine containing antigens from norovirus genotypes GI.1 and GII.4
Molecular Target Not applicable
Mechanism of ActionVaccine
Therapeutic ModalityPreventive vaccine: Viral vaccine
Latest Stage of DevelopmentPhase II
Standard IndicationGastrointestinal infection
Indication DetailsPrevent acute gastroenteritis due to norovirus infection; Prevent moderate or severe acute gastroenteritis due to norovirus infection
Regulatory Designation
PartnerGlaxoSmithKline plc

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today